CD19 and Autoimmunity: Third, indication expansion into autoimmunity is accelerating and likely to normalize short‐course, drug‐free remissions: early CD19‐CAR‐T programs (e.g., CABA‐201) show encouraging activity, while allogeneic hypoimmune CAR‐T is advancing in autoimmune cohorts and has already induced remission in refractory SLE; iPSC‐derived products are entering the same space and may decouple supply from donor variability.